Biomarcadores séricos en el traumatismo craneoencefálico: utilidad clínica actual
Salud Medicina e Innovación Journal · 05.08.2026 · 4 (3) · 283-300
DOI: 10.70577/hcx64d58 ↗Kurz gefasst
Fachartikel in der Zeitschrift Salud Medicina e Innovación Journal, online erschienen am 05.08.2026. Verfasst von Jimmy Fernando Yaguana Torres und 4 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Introduction
Traumatic brain injury is a heterogeneous clinical condition whose assessment, particularly in mild cases, may be limited when based solely on neurological examination, the Glasgow Coma Scale, and clinical decision rules. In this context, serum biomarkers have emerged as complementary tools for detecting intracranial injury, guiding computed tomography use, and estimating prognosis.
Objective
To analyze the current clinical utility of the main serum biomarkers in traumatic brain injury, with emphasis on their diagnostic, prognostic, and follow-up value. Methodology: A structured narrative review with a systematized literature search was conducted using PubMed, Scopus, and ScienceDirect. A total of 654 records were identified, 19 duplicates were removed, and 90 full-text articles were assessed. Finally, 25 studies were included based on their relevance to the objectives of the review and their contribution to the analysis of the current clinical utility of serum biomarkers in traumatic brain injury.
Results
GFAP and UCH-L1 showed the greatest utility for ruling out intracranial injuries because of their high sensitivity and negative predictive value, although their specificity was limited. S100B showed favorable results as a rule-out test, particularly in pediatric populations, but its performance depends on the sampling time window and the presence of extracranial injuries. NfL and tau showed greater potential for assessing axonal injury, neurological evolution, and functional outcomes.
Conclusion
Serum biomarkers do not replace clinical assessment or computed tomography. Their greatest utility is achieved when they are integrated with clinical decision rules, neuroimaging, and temporal follow-up.
Zitieren
APA
Torres, J. F. Y., Yaguana, W. S. M., Valdiviezo, I. D. L., Navarrete, F. N. I., & Hidalgo, Y. A. R. (2026). Biomarcadores séricos en el traumatismo craneoencefálico: utilidad clínica actual. Salud Medicina e Innovación Journal, 4(3), 283-300. https://doi.org/10.70577/hcx64d58
Vancouver
Torres JFY, Yaguana WSM, Valdiviezo IDL, Navarrete FNI, Hidalgo YAR. Biomarcadores séricos en el traumatismo craneoencefálico: utilidad clínica actual. Salud Medicina e Innovación Journal. 2026;4(3):283-300. doi:10.70577/hcx64d58
BibTeX
@article{Torres2026,
author = {Torres, Jimmy Fernando Yaguana and Yaguana, Wendy Scarlett Medina and Valdiviezo, Irene Diana León and Navarrete, Fernanda Nicole Iñiguez and Hidalgo, Yiliam Ahylie Rojas},
title = {Biomarcadores séricos en el traumatismo craneoencefálico: utilidad clínica actual},
journal = {Salud Medicina e Innovación Journal},
year = {2026},
volume = {4},
number = {3},
pages = {283--300},
doi = {10.70577/hcx64d58}
}
EUVIMED